BIBW 2992 in non-small cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 20, Issue 3, 2011, Pages 415-422

  Subramaniam, Deepa S ^a   Hwang, Jimmy ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

afatinib; BIBW 2992; EGFR inhibitor resistance; EGFR inhibitors; non small cell lung cancer

Indexed keywords

AFATINIB; ARGININE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEFITINIB; LEUCINE; METHIONINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; THREONINE; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; AMINO ACID SUBSTITUTION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CLINICAL FEATURE; DEPHOSPHORYLATION; DIARRHEA; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERTRANSAMINASEMIA; IC 50; KIDNEY FUNCTION; LIPID DIET; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOLID TUMOR; STOMATITIS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79951638032     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.557063     Document Type: Review

References (33)

1. Sibilia M, Kroismayr R, Lichtenberger BM, et al. the epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2008;75(9):770-87
2. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41(Suppl 1):S32-7
3. Kancha RK, von Bubnoff N, Peschel C, et al. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009;15:460-7
4. Gazdar AF. Activating and resistance mutations of EGFR in non-small cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S24-31
5. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(3 Pt 1):839-44 (Pubitemid 43259866)
6. Leidner RS, Fu P, Clifford B, et al. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 2009;27(33):5620-6
7. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44 (Pubitemid 41058345)
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32 (Pubitemid 41058344)
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39 (Pubitemid 38637993)
10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
11. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13(10):2890-6 (Pubitemid 46849563)
12. Kono SA, Marshall ME, Ware KE, Heasley LE. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Update 2009;12(4-5):95-102
13. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib, Clin Cancer Res 2006;12(19):5764-9 (Pubitemid 44629607)
14. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008;26(10):1742-51
15. Clark J, Cools J, Gilliland DG. EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. PLoS Med 2005;2:e75
16. Yun CH, Mengwasser KE, Toms AV, et al. the T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-5 (Pubitemid 351439466)
17. van der Veeken J, Oliveira S, Schiffelers RM. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009;9(6):748-60
18. Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010;16(22):5489-98
19. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27(34):4702-11
20. Regales L, Gong Y, Shen R. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119(10):3000-10
21. Eskens FALM, Mom CH, Planting AST, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008;98:80-5
22. Stopfer P, Narjes H, Gaschler-Markefski B, et al. Pharmacokinetics (PK) of [14C]-BIBW 2992 after administration of a single dose of 15 mg [14C]-BIBW 2992 oral solution in healthy male volunteers. J Clin Oncol 2008;26(18 Suppl):abstract 14607
23. Lewis N, Marshall J, Amelsberg A, et al. A phase I dose escalation schedule of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors [abstract 3091]. J Clin Oncol 2006;24(18 Suppl):143s
24. Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28(925):3965-72
25. Agus DB, Terlizzi E, Stopfer P, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/ER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours [abstract 2074]. J Clin Oncol 2006;24(18 Suppl):97s
26. Vermorken JB, Machiels JH, Rottey S, et al. Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cipslatin/5FU (PF), in patients with advanced solid tumors. J Clin Oncol 2010;28(18 Suppl):abstract e13521
27. Ang J, Mikropoulos C, Stavridi F, et al. A phase I study of daily BIBW 2992, an irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel. J Clin Oncol 2009;27(18 Suppl):abstract e14541
28. Awada AH, Dumez H, Wolter P, et al. A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three weekly docetaxel in patients with advanced solid tumors. J Clin Oncol 2009;27(18 Suppl):abstract 3556
29. Yang C, Hirsch J, Cadranel Y, et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): A preliminary report. J Clin Oncol 2009;27(Suppl 15s):abstract 8062
30. Miller VA, Hirsh V, Cadranel J, et al. Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo 1 + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1). Ann Oncol 2010;21(Suppl 8):viii1. Abstract LBA1
31. Yang C, Shih J, Su W, et al. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J Clin Oncol 2010;28(Suppl 15s):abstract 7521
32. Bean J, Riely GJ, Balak M, et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008;14(22):7519-25
33. Takezawa K, Okamoto I, Tanizaki J, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 2010;9(6):1647-56